Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 December 2023 | Story LUNGA LUTHULI | Photo SUPPLIED
Milton Mogotsi
Charting unexplored territories: Milton Mogotsi, UFS PhD student, clinches victory in National 3MT Competition, unravelling infant enteric virome complexities, poised to revolutionise virology.

Milton Mogotsi, a PhD student at the University of the Free State (UFS), has secured a remarkable victory in the esteemed National 3 Minute Thesis competition (3MT), rising above formidable competition nationwide. This achievement follows Mogotsi’s earlier successes at faculty and institutional levels, where his presentations on the enteric virome of infants in the Free State stood out for their brilliance and significance.

The annual competition serves as a platform for postgraduate students to enhance their academic, presentation, and research communication skills by succinctly explaining their research to an intelligent but non-specialist audience within a concise 3-minute timeframe.

Reflecting on his initial reaction to the news, Mogotsi expressed a mix of shock and excitement. “I was genuinely shocked and excited when declared the winner,” he shared. This victory marked a significant milestone for Mogotsi, as a first-time participant, showcasing the excellence of both the UFS and the Faculty of Health Sciences.

Exploring uncharted territories

Mogotsi’s groundbreaking research delves into the unexplored domain of the enteric virome in infants, a subject inspired by his earlier master’s study in microbiology. “I was first introduced to this research during my master’s degree, and compelling findings motivated me to pursue further studies,” explained Mogotsi. Guided by his mentor, Prof Martin Nyaga, Mogotsi's doctoral journey unfolded into a profound exploration of the complexities of viruses colonising infants' guts and their implications on infant health.

Sharing key findings, Mogotsi highlighted that, despite detecting several disease-causing viruses in infants’ guts, none exhibited clinical symptoms. This emphasises the role of immunity and protective measures like breastfeeding. He also identified plant viruses, potentially transmitted through the environment or food sources, raising intriguing questions about infants’ exposure.

His pioneering use of viral metagenomics in unravelling the enteric virome’s complexity underscored its potential in understanding human health and disease. “Viral metagenomics has become a fundamental tool, shedding light on the composition of the infant’s enteric virome,” explained Mogotsi. 

Navigating challenges

Despite challenges, including disruptions due to COVID-19 and participant withdrawals, Mogotsi persevered, underscoring the importance of a longitudinal approach in comprehending the infant virome’s development over time. His success in the competition not only boosted his confidence but also expanded his networks, providing invaluable opportunities to present his findings internationally.

Mogotsi's advice to aspiring researchers mirrors his own journey: clarity of purpose, resilience in the face of challenges, fostering mentor relationships, and making the most of available resources. His groundbreaking work is poised to influence policy, guide vaccine strategies, and reshape our understanding of infant health.

As Mogotsi approaches the completion of his PhD, the future holds promising horizons for this trailblazing researcher, poised to leave an indelible mark on the world of virology and infant health.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept